Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Haluska

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptorJohann S de Bono, Gerhardt Attard, Alex Adjei, et al.
Investigational New Drugs|September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignanciesJoleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Cancer Research|January 7, 2006
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417Paul Haluska, Joan M Carboni, David A Loegering, et al.
Cancer Research|March 12, 2009
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsMarta Santisteban, Jennifer M Reiman, Michael K Asiedu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyWilliam J Gradishar, Denise A Yardley, Rachel Layman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Gynecologic Oncology|March 7, 2016
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcomeEvan Delgado, Michelle M Boisen, Robin Laskey, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptorJohann S de Bono, Gerhardt Attard, Alex Adjei, et al.
Investigational New Drugs|September 13, 2021
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignanciesJoleen M Hubbard, Jun Yin, Erin L Schenk, et al.
Cancer Research|January 7, 2006
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417Paul Haluska, Joan M Carboni, David A Loegering, et al.
Cancer Research|March 12, 2009
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsMarta Santisteban, Jennifer M Reiman, Michael K Asiedu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine TherapyWilliam J Gradishar, Denise A Yardley, Rachel Layman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Breast Cancer Research and Treatment|April 14, 2021
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)Tufia C Haddad, Jun He, Ciara C O'Sullivan, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
Gynecologic Oncology|March 7, 2016
High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcomeEvan Delgado, Michelle M Boisen, Robin Laskey, et al.
Pageof 7